GlassScriptPhysician profile
Jennifer Cruz
NPI 1427323195
$1,679.46
in general payments reported to CMS, 2019-2025
13 companies · $777 in 2025
The $777 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.29 · 2023: $401 · 2024: $484 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,662.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $350.10 | 2025 | Breztri, Fasenra |
| Medtronic, INC. | $236.42 | 2025 | Symplicity G3 |
| Alnylam Pharmaceuticals INC. | $214.39 | 2024-2025 | Onpattro, Givlaari |
| Novo Nordisk INC | $130.00 | 2023 | Wegovy |
| Eisai INC. | $125.00 | 2024 | |
| Coloplast Corp | $119.09 | 2024 | |
| Amarin Pharma, INC. | $107.61 | 2023 | |
| Biogen, INC. | $100.00 | 2023 | Spinraza |
| Regeneron Healthcare Solutions, INC. | $85.47 | 2024 | Dupixent |
| Neurocrine Biosciences, INC. | $75.00 | 2024 | Ingrezza |
| Abbott Laboratories | $63.80 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Cipher Pharmaceuticals US LLC | $55.29 | 2025 | Natroba, Spinosad |
| Edwards Lifesciences Corporation | $17.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Cruz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.